Abstract
1. This was an 18-week prospective, randomised, double-blind, placebo-controlled clinical study on a Chinese herbal medicine—MaZiRenWan (MZRW)—for the treatment of functional constipation.
2. 120 subjects with functional (Rome III criteria) were randomised (60 per arm) into the MZRW and placebo groups. Respective responder rates for the two groups were 43.3% and 8.3% during treatment, and 30.0% and 15.0% in the follow-up period (p 3. The dose of MZRW (7.5 g bid) was determined in a separate clinical trial. This study entailed a dose determination study and then a placebo-controlled clinical trial and can be a good reference for future studies.
2. 120 subjects with functional (Rome III criteria) were randomised (60 per arm) into the MZRW and placebo groups. Respective responder rates for the two groups were 43.3% and 8.3% during treatment, and 30.0% and 15.0% in the follow-up period (p 3. The dose of MZRW (7.5 g bid) was determined in a separate clinical trial. This study entailed a dose determination study and then a placebo-controlled clinical trial and can be a good reference for future studies.
| Original language | English |
|---|---|
| Pages (from-to) | S44-S46 |
| Number of pages | 3 |
| Journal | Hong Kong Medical Journal |
| Volume | 19 |
| Issue number | 6, Suppl 9 |
| Publication status | Published - Dec 2013 |
Scopus Subject Areas
- General Medicine